Radioimmunotherapy in non-Hodgkin's lymphoma: Focus on 90Y-ibritumomab tiuxetan (Zevalin®)

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 4, 2004, Pages 305-316

  White, Christine A ^a  

^a BIOGEN   (United States)

Author keywords

Ibritumomab tiuxetan; Immunotherapy; Non Hodgkin's lymphoma; Radioimmunotherapy; Rituximab

Indexed keywords

ANTIBODY CONJUGATE; DACLIZUMAB; DACLIZUMAB Y 90; EPRATUZUMAB; EPRATUZUMAB Y 90; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ANEMIA; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING KINETICS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXICITY; DOSIMETRY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; MAXIMUM ALLOWABLE CONCENTRATION; META ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE, TUMOR; CLINICAL TRIALS; HUMANS; LYMPHOMA, NON-HODGKIN; MODELS, MOLECULAR; RADIOIMMUNOTHERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 13244283151     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424-1433, 1984.
2. Ansell SM, Ristow KM, Habermann TM et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20:3885-3890, 2002.
3. 90Y-Zevalin®) [abstract]. 2003 Pan-Pacific Lymphoma Conference, July 21-26 2003, Kohala Coast, Hawaii, Abstract.
4. Ansell SM, Schilder RJ, Pieslor PC, et al. Feasibility of Anti-Lymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature. Clinical Lymphoma 2004 (in press)
5. Biogen Idec. Zevalin® (Ibritumomab tiuxetan) prescribing information. 2002.
6. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 19:129-150, 2001.
7. Chang KL, Arber DA, Weiss LM. CD20: A review. Applied Immunohistochem 4:1-15, 1996.
8. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999.
9. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15:1017-1025, 1999.
10. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma [abstract]. Proc Am Soc Clin Oncol 21, 266a. Abstract 1062. 2002a.
11. Davies AJ, Rohatiner AZS, Howell S, et al. Durable remissions and minor late toxicity may be obtained in patients treated at first or second recurrence of B cell non-Hodgkin's lymphoma (NHL) with tositumomab and I 131 tositumomab [abstract]. Proc Am Soc Clin Oncol 22, 598. Abstract 2405. 2003.
12. 131I-Lym-1 antibody. Cancer Biother Radiopharm 13:239-254, 1998.
13. Emmanouilides C, Murray JL, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy [abstract]. Blood 102(11), Abstract 4949. 2003a.
14. Emmanouilides C, Witzig T E, Gordon L, et al. Zevalin™ radioimmunotherapy (RIT) is safe and effective in geriatric patients with low-grade, follicular, or CD20+ transformed (LG/F/T) non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol 20, 286a. Abstract 1143. 2001.
15. Emmanouilides C E, Witzig T E, Molina A, et al. Improved safety and efficacy of Yttrium-90 Ibritumomab Tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell Non-Hodgkin's Lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol 22, 595. Abstract 2392. 2003b.
16. Emmanoulides CE, Czuczman MS, Revell S, et al. Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan. Proc Am Soc Clin Oncol 22, 14S. Abstract 6696, 2004.
17. Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79:493-500, 2000.
18. Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Int J Rad Appl Instrum B 18:369-381, 1991.
19. Gordon LI, Witzig T, Molina A, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma: updated results of a randomized controlled trial. Clin Lymphoma 5(2):98-101, 2004a.
20. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ b-cell lymphoma: long-term follow-up of a phase I/II study. Blood, 103(12):4429-4431, 2004b.
21. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity [abstract]. Proc Am Soc Clin Oncol 21, 266a. Abstract 1061. 2002.
22. Gordon LI, Witzig TE, Murray JL, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: final results of a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 22, 576. Abstract 2315. 2003.
23. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20(Suppl 5):75-88, 1993.
24. Jaffe ES, Harris NL, Stein H et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
25. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 43:1507-1529, 2002.
26. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000.
27. Kaminski MS, Tuck M, Regan D et al. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar®) [abstract]. Blood 100, 356a. Abstract 1381. 2002.
28. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14:435-443, 1987.
29. Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278, 1998.
30. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997.
31. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 29(Suppl 2):2-9, 2002.
32. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
33. Nademanee A, Molina A, Forman SJ, et al. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 100(11), 182a. Abstract 679. 2002.
34. 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 40:2014-2020, 1999.
35. 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res 20:3647-3655, 2000.
36. Pedersen-Bjergaard J, Ersboll J, Sorensen HM et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195-200, 1985.
37. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999.
38. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987.
39. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993.
40. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995.
41. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000.
42. Press OW, Leonard JP, Coiffier B et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology (Am Soc Hematol Educ Program)221-240, 2001. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm 11:43-50, 1996.
43. Press OW, Leonard JP, Coiffier B et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology (Am Soc Hematol Educ Program)221-240, 2001. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm 11:43-50, 1996.
44. Schilder RJ, Molina A, Bartlett N et al. Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Therapy and Biopharmaceuticals 19(4):478-481, 2004.
45. Stashenko P, Nadler LM, Hardy R et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980.
46. Vose J M, Bierman PJ, Lynch JC, et al. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-hodgkin's lymphoma (NHL): synergistic results with no added toxicity [abstract]. Proc Am Soc Clin Oncol 20, Abstract 19. 2001.
47. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000.
48. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43:267-272, 2002.
49. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 30:31-38, 2003.
50. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:638-645, 1984.
51. Winter JN, Inwards D, Erwin W et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results [poster]. Blood 100(11), 411a. Abstract 1597. 2003.
52. Wiseman GA, Colgan JP, Micallef IN et al. Interim safety results of a phase I trial of two sequential doses of yttrium-90 ibritumomab tiuxetan for previously treated patients with low-grade non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol 22, 575. Abstract 2312. 2003a.
53. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-4342, 2002.
54. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 44:465-474, 2003b.
55. Wiseman GA, Leigh BR, Dunn WL et al. Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy. Cancer Biother Radiopharm 18:253-258, 2003c.
56. 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma [abstract]. J Nucl Med 42(5 Suppl), 268P. Abstract 1124. 2001a.
57. Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-194, 2001b.
58. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777, 2000.
59. Witzig TE, Emmanouilides C, Molina A et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRU) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol 22, 597. Abstract 2400. 2003a.
60. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002a.
61. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract]. Proc Am Soc Clin Oncol 21, 266a. Abstract 1063. 2002b.
62. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002c.
63. Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003b.
64. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999.
65. Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med 41:297-308, 2000.